Krishna Institute of Medical Sciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+28.7%+21.1%
EBITDA+2.4%+9.9%
Net Income−41.7%−12.9%
EPS (adj.)−37.2%−10.5%
Total Assets+35.3%+38.2%
Total Equity+5.8%+9.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

KIMS₹704.60

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISJUBLPHARMAINDGNONESOURCEPFIZERPOLYMEDMcap ₹28,184 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+28.7+21.1
EBITDA+2.4+9.9
Net Income-41.7-12.9
EPS (adj.)-37.2-10.5
Total Assets+35.3+38.2
Total Equity+5.8+9.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.